Skip to search formSkip to main contentSkip to account menu

AVP-923

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Market watch: Upcoming market catalysts in Q4 2010
Several important US Food and Drug Administration (FDA) approval decisions are expected in the fourth quarter of 2010. First, the… 
2006
2006
AVP-923 as a Novel Treatment for Pseudobulbar Affect in ALS
2006
2006
PII‐59
2006
2006
PR_149: Episode-Free Weekly Remission Rates With AVP-923 in the Treatment of Involuntary Emotional Expression Disorder
2006
2006
PR_160: Time to Response With AVP-923 in Patients With Involuntary Emotional Expression Disorder
2005
2005
Treatment of pseudobulbar affect in ALS: October 26 Highlight and Commentary
The study by Brooks et al.1 demonstrating positive effects of dextromethorphan/quinidine (DM/Q) in the treatment of pseudobulbar… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)